Literature DB >> 33661423

Is function-based resection using intraoperative awake brain mapping feasible and safe for solitary brain metastases within eloquent areas?

Jean-Baptiste Pelletier1,2,3, Alessandro Moiraghi1,2,4,5, Marc Zanello1,2,6, Alexandre Roux1,2,6, Sophie Peeters7, Bénédicte Trancart1,2, Myriam Edjlali2,6,8, Emmanuele Lechapt2,9, Arnault Tauziede-Espariat2,9, Gilles Zah-Bi1,2, Eduardo Parraga1,2, Fabrice Chretien2,9, Edouard Dezamis1,2, Frédéric Dhermain10, Johan Pallud11,12,13.   

Abstract

To assess feasibility and safety of function-based resection under awake conditions for solitary brain metastasis patients. Retrospective, observational, single-institution case-control study (2014-2019). Inclusion criteria are adult patients, solitary brain metastasis, supratentorial location within eloquent areas, and function-based awake resection. Case matching (1:1) criteria between metastasis group and control group (high-grade gliomas) are sex, tumor location, tumor volume, preoperative Karnofsky Performance Status score, age, and educational level. Twenty patients were included. Intraoperatively, all patients were cooperative; no obstacles precluded the procedure from being performed. A positive functional mapping was achieved at both cortical and subcortical levels, allowing for a function-based resection in all patients. The case-matched analysis showed that intraoperative and postoperative events were similar, except for a shorter duration of the surgery (p<0.001) and of the awake phase (p<0.001) in the metastasis group. A total resection was performed in 18 cases (90%, including 10 supramarginal resections), and a partial resection was performed in two cases (10%). At three months postoperative months, none of the patients had worsening of their neurological condition or uncontrolled seizures, three patients had an improvement in their seizure control, and seven patients had a Karnofsky Performance Status score increase ≥10 points. Function-based resection under awake conditions preserving the brain connectivity is feasible and safe in the specific population of solitary brain metastasis patients and allows for high resection rates within eloquent brain areas while preserving the overall and neurological condition of the patients. Awake craniotomy should be considered to optimize outcomes in brain metastases in eloquent areas.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Awake surgery; Brain metastasis; Extent of resection; Feasibility; Intraoperative brain mapping; Safety

Mesh:

Year:  2021        PMID: 33661423     DOI: 10.1007/s10143-021-01504-6

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  11 in total

1.  Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain.

Authors:  F B Meyer; L M Bates; S J Goerss; J A Friedman; W L Windschitl; J R Duffy; W J Perkins; B P O'Neill
Journal:  Mayo Clin Proc       Date:  2001-07       Impact factor: 7.616

2.  Risk factors for early death after surgery in patients with brain metastases: reevaluation of the indications for and role of surgery.

Authors:  Hideyuki Arita; Yoshitaka Narita; Yasuji Miyakita; Makoto Ohno; Minako Sumi; Soichiro Shibui
Journal:  J Neurooncol       Date:  2013-10-25       Impact factor: 4.130

3.  Technical principles of direct bipolar electrostimulation for cortical and subcortical mapping in awake craniotomy.

Authors:  J Pallud; E Mandonnet; R Corns; E Dezamis; E Parraga; M Zanello; G Spena
Journal:  Neurochirurgie       Date:  2017-05-12       Impact factor: 1.553

4.  Peri- and intraoperative cognitive and language assessment for surgical resection in brain eloquent structures.

Authors:  G Herbet; O Rigaux-Viodé; S Moritz-Gasser
Journal:  Neurochirurgie       Date:  2017-05-12       Impact factor: 1.553

5.  Awake mapping optimizes the extent of resection for low-grade gliomas in eloquent areas.

Authors:  Alessandro De Benedictis; Sylvie Moritz-Gasser; Hugues Duffau
Journal:  Neurosurgery       Date:  2010-06       Impact factor: 4.654

6.  EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force.

Authors:  R Soffietti; P Cornu; J Y Delattre; R Grant; F Graus; W Grisold; J Heimans; J Hildebrand; P Hoskin; M Kalljo; P Krauseneck; C Marosi; T Siegal; C Vecht
Journal:  Eur J Neurol       Date:  2006-07       Impact factor: 6.089

7.  Functional-Based Resection Does Not Worsen Quality of Life in Patients with a Diffuse Low-Grade Glioma Involving Eloquent Brain Regions: A Prospective Cohort Study.

Authors:  Jun Muto; Edouard Dezamis; Odile Rigaux-Viode; Sophie Peeters; Alexandre Roux; Marc Zanello; Charles Mellerio; Xavier Sauvageon; Pascale Varlet; Catherine Oppenheim; Johan Pallud
Journal:  World Neurosurg       Date:  2018-02-09       Impact factor: 2.104

Review 8.  Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective.

Authors:  Hugues Duffau
Journal:  Curr Opin Oncol       Date:  2018-11       Impact factor: 3.645

9.  Retrospective study of 127 surgically treated patients with multiple brain metastases: indication, prognostic factors, and outcome.

Authors:  Gabriele Schackert; Claudia Lindner; Saskia Petschke; Mario Leimert; Matthias Kirsch
Journal:  Acta Neurochir (Wien)       Date:  2013-01-13       Impact factor: 2.216

10.  Management of single brain metastasis: a practice guideline.

Authors:  A Mintz; J Perry; K Spithoff; A Chambers; N Laperriere
Journal:  Curr Oncol       Date:  2007-08       Impact factor: 3.677

View more
  1 in total

1.  Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom.

Authors:  Matthias Schneider; Patrick Schuss; Majd Bahna; Muriel Heimann; Christian Bode; Valeri Borger; Lars Eichhorn; Erdem Güresir; Motaz Hamed; Ulrich Herrlinger; Yon-Dschun Ko; Felix Lehmann; Anna-Laura Potthoff; Alexander Radbruch; Christina Schaub; Rainer Surges; Johannes Weller; Hartmut Vatter; Niklas Schäfer
Journal:  Neurosurg Rev       Date:  2021-05-14       Impact factor: 2.800

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.